洛铂联合长春瑞滨治疗晚期乳腺癌的疗效及安全性  

Efficacy and Safety of Lobaplatin Combined with Vinorelbine in Treatment of Advanced Breast Cancer

作　　者：张素贞[1] 张国耀[2] 史磊[2] 

机构地区：[1]漯河市中心医院中心药房,河南漯河462000 [2]漯河市中心医院肿瘤科,河南漯河462000

出　　处：《中国医院用药评价与分析》2017年第5期612-613,616,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨洛铂联合长春瑞滨治疗晚期乳腺癌的临床疗效及安全性。方法:选择2014年3月—2016年5月收治的60例晚期乳腺癌患者,按照随机数字表法分为观察组和对照组,每组30例。观察组患者给予洛铂联合长春瑞滨治疗,对照组患者给予顺铂联合长春瑞滨治疗,比较两组患者的临床疗效与不良反应发生情况。结果:观察组患者的有效率为86.67%(26/30)、对照组为76.67%(23/30),观察组患者的临床获益率为90.00%(27/30)、对照组为93.33%(28/30),两组的差异均无统计学意义(P>0.05);两组患者肿瘤进展中位时间和中位生存期的差异无统计意义(P>0.05);两组患者常见不良反应为恶心呕吐、肝损害、骨髓抑制、静脉炎及脱发等,观察组患者恶心、呕吐发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:洛铂联合长春瑞滨治疗晚期乳腺癌的疗效确切,安全性较好,具有较高的临床应用价值。OBJECTIVE：To probe into the clinical efficacy and safety of lobaplatin combined with vinorelbine in treatment of advanced breast cancer. METHODS ： 60 patients with advanced breast cancer, admitted into Luohe Central Hospital from Mar. 2014 to May. 2016 were selected and divided into observation group and control group via the random number table, with 30 cases in each group. The observation group was treated with vinorelbine combined with lobaplatin, while the control group was given vinorelbine combined with cis-platinum, the clinical efficacy and adverse reactions of two groups were compared. RESULTS ： The total effective rate of observation group was 86. 67% （26/30）, that of the control group was 76. 67% （23/30） ; the clinical benefit rate of observation group was 90. 00% （27/30）, that of the control group was 93.33% （28/30）, with no statistical differences （P 〉 0. 05 ）. There was no statistical difference between two groups in median time to progression and median survival time （P 〉 0.05 ） ; The common adverse reactions in two groups were nausea, vomiting, liver function damage, bone marrow suppression, phlebitis and hair loss, etc. The incidence of nausea and vomiting in observation group was significantly lower than those of the control group, with statistically significant difference （P 〈 0. 05）. CONCLUSIONS treatment of advanced breast cancer is significant, with higher ： The efficacy of lobaplatin combined with vinorelbine in safety and clinical application value.

关 键 词：洛铂 长春瑞滨 晚期乳腺癌 化疗 

分 类 号：R979.1[医药卫生—药品]